Area of research
Infectious Diseases · Immunology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Immunotherapy and Immune Responses, and Animal Virus Infections Studies.
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
Mucosal boosting enhances vaccine protection against SARS-CoV-2 in macaques
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron
Vaccine protection against the SARS-CoV-2 Omicron variant in macaques
SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice
Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung
Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates
Correlates of protection against SARS-CoV-2 in rhesus macaques
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
SARS-CoV-2 infection protects against rechallenge in rhesus macaques
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Animal models for COVID-19
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
Vascular Disease and Thrombosis in SARS-CoV-2-Infected Rhesus Macaques
Correlates of protection against SARS-CoV-2 in rhesus macaques
DSpace@MIT (Massachusetts Institute of Technology) 2020cited by 17position: middle
Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination